In addition, nivolumab can be given as a monotherapy in locally advanced or metastasised NSCLC after chemotherapy or in the neo-adjuvant setting in resectable, low-PD-L1 (≥1%) NSCLC [18]. Here, CD274 is linked to non-small cell lung carcinoma.